Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Mathias Lutz, Arik B. Schulze, Elisabeth Rebber, Stefanie Wiebe, Tarek Zoubi, Oliver M. Grauer, Torsten Keßler, Andrea Kerkhoff, Georg Lenz, Wolfgang E. Berdel
Cancer Res Treat. 2017;49(2):548-552.   Published online 2016 Jul 12     DOI:
Citations to this article as recorded by Crossref logo
Neurological complications of new chemotherapy agents
Alicia M Zukas, David Schiff
Neuro-Oncology.2018; 20(1): 24.     CrossRef
Neuro-ophthalmic side effects of molecularly targeted cancer drugs
M T Bhatti, A K S Salama
Eye.2018; 32(2): 287.     CrossRef
Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency
S. A. Misbah
Clinical & Experimental Immunology.2017; 188(3): 342.     CrossRef
T cell therapies for human polyomavirus diseases
Sarah I. Davies, Pawel Muranski
Cytotherapy.2017; 19(11): 1302.     CrossRef
The safety profile of monoclonal antibodies for chronic lymphocytic leukemia
Anna Korycka-Wołowiec, Dariusz Wołowiec, Tadeusz Robak
Expert Opinion on Drug Safety.2016; : 1.     CrossRef